JP2024501403A5 - - Google Patents
Info
- Publication number
- JP2024501403A5 JP2024501403A5 JP2023532452A JP2023532452A JP2024501403A5 JP 2024501403 A5 JP2024501403 A5 JP 2024501403A5 JP 2023532452 A JP2023532452 A JP 2023532452A JP 2023532452 A JP2023532452 A JP 2023532452A JP 2024501403 A5 JP2024501403 A5 JP 2024501403A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213166.0 | 2020-12-10 | ||
| EP20213166 | 2020-12-10 | ||
| PCT/EP2021/085079 WO2022122973A1 (en) | 2020-12-10 | 2021-12-09 | Antibodies that bind gamma-delta t cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501403A JP2024501403A (ja) | 2024-01-12 |
| JP2024501403A5 true JP2024501403A5 (https=) | 2024-12-17 |
| JPWO2022122973A5 JPWO2022122973A5 (https=) | 2024-12-17 |
Family
ID=73793117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532452A Pending JP2024501403A (ja) | 2020-12-10 | 2021-12-09 | ガンマ－デルタｔ細胞受容体に結合する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303694A1 (https=) |
| EP (1) | EP4259660A1 (https=) |
| JP (1) | JP2024501403A (https=) |
| KR (1) | KR20230157933A (https=) |
| CN (1) | CN116888153A (https=) |
| AU (1) | AU2021395439A1 (https=) |
| CA (1) | CA3200826A1 (https=) |
| IL (1) | IL303045A (https=) |
| MX (1) | MX2023006832A (https=) |
| WO (1) | WO2022122973A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| WO2025128615A1 (en) * | 2023-12-12 | 2025-06-19 | Seagen Inc. | Multispecific egfr antibodies and use in the treatment of cancer |
| TW202535922A (zh) * | 2023-12-18 | 2025-09-16 | 美商思進公司 | 治療ｅｇｆｒ突變癌症之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| EP3129404B1 (en) * | 2014-04-10 | 2026-01-28 | LAVA Therapeutics N.V. | Immunoglobulins binding human vgamma9vdelta2 t cell receptors |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
-
2021
- 2021-12-09 IL IL303045A patent/IL303045A/en unknown
- 2021-12-09 CN CN202180090574.0A patent/CN116888153A/zh active Pending
- 2021-12-09 CA CA3200826A patent/CA3200826A1/en active Pending
- 2021-12-09 MX MX2023006832A patent/MX2023006832A/es unknown
- 2021-12-09 WO PCT/EP2021/085079 patent/WO2022122973A1/en not_active Ceased
- 2021-12-09 AU AU2021395439A patent/AU2021395439A1/en active Pending
- 2021-12-09 EP EP21824387.1A patent/EP4259660A1/en active Pending
- 2021-12-09 JP JP2023532452A patent/JP2024501403A/ja active Pending
- 2021-12-09 KR KR1020237023004A patent/KR20230157933A/ko active Pending
-
2023
- 2023-06-09 US US18/332,165 patent/US20230303694A1/en active Pending